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Background: Modified radical mastectomy remains the standard therapeutic surgical operation for breast cancer in
most parts of the world. This retrospective study reviews mastectomy for management of breast cancer in a
surgical oncology division over a ten year period.
Methods: We reviewed the case records of consecutive breast cancer patients who underwent mastectomy at the
Surgical Oncology Division, University College Hospital (UCH) Ibadan between November 1999 and October 2009.
Results: Of the 1226 newly diagnosed breast cancer patients over the study period, 431 (35.2%) patients
underwent mastectomy making an average of 43 mastectomies per year. Most patients were young women,
premenopausal, had invasive ductal carcinoma and underwent modified radical mastectomy as the definitive
surgical treatment. Prior to mastectomy, locally advanced tumors were down staged in about half of the patients
that received neo-adjuvant combination chemotherapy. Surgical complication rate was low. The most frequent
operative complication was seroma collection in six percent of patients. The average hospital stay was ten days and
most patients were followed up at the surgical outpatients department for about two years post-surgery.
Conclusions: There was low rate of mastectomy in this cohort which could partly be attributable to late
presentation of many patients with inoperable local or metastatic tumors necessitating only palliative or terminal
care. Tumor down-staging with neo-adjuvant chemotherapy enhanced surgical loco-regional tumor control in some
patients. The overall morbidity and the rates of postoperative events were minimal. Long-term post-operative
out-patients follow-up was not achieved as many patients were lost to follow up after two years of mastectomy.
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Surgery is the oldest treatment modality for cancer [1].
Its role has evolved over time to include prevention,
diagnosis, treatment and rehabilitation. Total colectomy
for familial adenomatous polyposis coli, prophylactic
mastectomy and oophorectomy in people with familial
risks for breast and ovarian cancers are all examples of
cancer prevention surgery. Endoscopic and open surgical
biopsies enhance tissue retrieval for the all-important
pathological diagnosis and characterization of solid tu-
mors. For many solid cancers, local and regional control
is achieved by total surgical extirpation, or sometimes* Correspondence: toogundiran@yahoo.co.uk
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reproduction in any medium, provided the orpartial debulking, of the primary tumorr and the adjoin-
ing lymph nodes. Surgery is also increasingly employed
in the management of solitary cancer metastases and in
post treatment reconstruction and rehabilitation.
The role of surgery in the management of breast can-
cer consists in diagnosis, loco-regional tumor control in
form of mastectomy and axillary dissection, and breast
reconstruction. Vascular access for adjuvant chemothe-
rapy and other parenteral infusions is often facilitated
through outpatient surgical procedures. Furthermore, in
metastatic breast cancer, surgical procedures are indi-
cated for draining pleural effusions, stabilization bone
and spine fractures and excising solitary deposits in the
brain among others.
The surgical treatment of breast cancer has gone
through phases. The early conservative excision gave
way to Halsted’s radical mastectomy and this, with itstral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ment for over a century [2]. In modern times, the use of
conservative surgery as part of multidisciplinary manage-
ment of breast cancer is increasing throughout the world.
Complete surgical removal of the breast with its local
lymphatic drainage remains the preferred surgical treat-
ment in many parts of the world, especially in low income
countries (LICs) where breast conserving surgery is in-
frequently practiced. This is because of the late stage of
presentation of most patients, the large size of tumors at
diagnosis, and the aggressive nature of the disease in a
predominantly young population of women [3,4]. More-
over, breast conserving surgery in LICs is faced with
many challenges including logistics limitations such as
paucity of radiotherapy services and inefficient follow-
up programmes.
There have been many publications on the surgical
management of breast cancer from developed countries
but few from developing countries [5-8]. In this paper
we present findings from a review of breast cancer
patients who had mastectomy in our division over a ten
year period.
Methods
We reviewed the case records of consecutive breast can-
cer patients who underwent mastectomy at the Surgical
Oncology Division, University College Hospital (UCH)
Ibadan between November 1999 and October 2009. A
consultant surgeon supervised surgical residents and in-
terns to extract data from wards admission registers,
theater records and the division’s operation register and
histology reports of mastectomy specimens. The infor-
mation from those documents was used to retrieve the
patients’ case files from the hospital records department.
Individual patient’s consent was not required for this
study due to its retrospective nature and being a reviewFigure 1 Numbers of breast cancer patients seen and mastectomies d
in 1999–2009.of routine clinical activities. However, permission was
sought from the Chairman, Medical Advisory Commit-
tee (CMAC) of the hospital who doubles statutorily as
the Vice Chairman of the University of Ibadan and Uni-
versity College Hospital Research Ethics Committee be-
fore accessing the patients’ information at the medical
records department.
We recorded the patients’ demographics, breast cancer
diagnosis, treatment modalities and outcomes of care.
All the patients had pathological confirmation of breast
cancer diagnosis by either needle or open surgical bi-
opsy. Pathological diagnosis consisted of the histological
type in all the patients and immunohistochemistry in
some of them. The staging investigations recorded were
mainly plain chest radiograph and abdomino-pelvic ul-
trasonography, radionuclide bone scan was added in the
latter three years of the study. The information obtained
from the patients’ case files were recorded in Microsoft
excels spreadsheet. Descriptive methods were used to
characterize the patients demography, clinical presen-
tation, stage, treatments offered including types of mas-
tectomy done and the outcomes of surgical treatment.
Statistical analysis was done using SPSS version15 and
the results are presented in charts and graphs.
Results
We retrieved the records of 1226 newly diagnosed breast
cancer patients over the study period. Of these, 431
(35.2%) patients underwent mastectomy making an ave-
rage of 43 mastectomies per year. Figure 1 shows the
number of cases diagnosed and number that underwent
mastectomy every year of the study. The case files of
354 patients constituting 82.1% of all mastectomies were
available for review.
Table 1 shows the socio-demographic characteristics
of the patients who had mastectomy. They were agedone per year in Surgical Oncology Division, UCH Ibadan
Table 1 Selected characteristics of breast cancer patients
who had mastectomy in Surgical Oncology Division, UCH
Ibadan in 1999–2009
Characteristic Mean (SD) No (n = 354) %






















Family history of breast cancer 18 5.1





Not known or applicable 8 2.3
Height (cm) 162 (7.1)
Weight (kg) 63.0 (15.3)
Body mass index (kg/m2) 24.01 (4.0)
SD, Standard deviation.
Table 2 Clinico-pathological characteristics of breast
cancer patients who had mastectomy in Surgical
Oncology Division, UCH Ibadan in 1999–2009
Characteristic Mean (SD) No* %





Axillary lymph nodes involvement
Yes 189 53.4
No 89 25.1
Not stated 76 21.5
Distant metastasis 49 17.1




Other bones 6 10.9
Histology type
Invasive ductal 249 70.3
Others 105 29.7
Immunochemistry ER (n = 185)
Positive 110 59.5
Negative 75 40.5
Immunochemistry PR (n = 185)
Positive 97 52.4
Negative 88 47.6
Immunochemistry Her 2 neu (n = 185)
Positive 38 20.5
Negative 147 79.5
SD, Standard deviation; * n = 354 unless otherwise stated.
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and a median of 43 years. As expected, the majority of
patients (340, 96.0%), were females. Most were Yorubas
(258, 73.0%), married (324, 91.5%), traders (136, 38.5%),
and of the Christian religion (289, 81.8%). Some patients
(18, 5.1%) reported a family history of breast cancer.
About half of the patients (188, 55.3%) were premeno-
pausal and 144 (42.4%) were postmenopausal. The me-
nopausal status was not known in 8 (2.3%) patients. The
mean age at menarche was 14.9 (2.2) years while the
mean body mass index was 24.01 (4.0) kg/m2.Clinical and pathology information
Table 2 shows the clinical and pathological characte-
ristics of the patients. The duration of breast lump be-
fore presentation at the UCH Ibadan ranged from 1
to 84 months with a mean (SD) of 12.3(14.4) months.
Breast cancer occurred in the right breast in 184 (52.2%)
patients while left sided and bilateral tumors were found
in 164 (46.4%) and 6 (1.4%) patients respectively. Clini-
cally, axillary node involvement was seen in 189 (53.4%)
patients, absent in 89 (25.1%) and not stated in 76 (21.5%)
patients. The patients were grouped into disease stages as
follows: stage I, 89 (25.0%); stage II, 188 (55.4%); stage III,
28 (7.8%); and stage IV, 49 (13.8%).
The main sites of metastasis were lung (25, 7.0%),
spine (11, 3.1%), liver (7, 2.0%) and other bones (6, 1.7%).
Invasive ductal carcinoma was the commonest histological
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sults were available for the tumors of 185 (52.3%) patients.
Of these, 110 (59.5%) were estrogen receptor (ER) positive,
97 (52.4%) were progesterone receptor (PR) positive and
38 (20.5%) were HER 2 positive.
Adjuvant treatment
Altogether, 315 (89.0%) patients received anti-cancer che-
motherapy. Of these, 174 (49.1%) patients were treated in
the neo-adjuvant setting, 127 (35.9%) post mastectomy
and 14 patients (4.0%) both pre and post-mastectomy
(Figure 2). Figures 3 and 4 respectively depicts the drug
regimens and tumor response in the 174 patients that
received neo-adjuvant combination chemotherapy. The
anticancer drugs were sourced mainly from the hospital
pharmacy and most of the patients completed 4 to 6
courses depending on the regimen used. Payment for the
drugs was out-of-pocket and the choice of regimen was
dictated mainly by cost and affordability by the patients.
Of the 174 patients, 63 and 56 had complete and partial
clinical response respectively, amounting to an overall
clinical response rate of 67.7%. Tumour dimensions were
assessed using caliper and hand measurements, and these
were corroborated with the histological reports of mastec-
tomy specimens in some cases. The commonly adminis-
tered chemotherapy regimens consisted of standard doses
of CMF, CAF, and AC and tumor response rate by drugs
is as shown in Table 3. Most of the patients received AC
regime because of the shift in the unit’s policy sometimes
during the period of this review from a combination of
CAF to AC. Further to surgery and chemotherapy, 212
(67.0%) and 119 (37.7%) patients received adjuvant radio-
therapy and hormonal therapy respectively. Hormonal
therapy consisted mainly of daily dose of 20 mg tamoxifen
for at least 2 years.
Surgical treatment
Modified radical mastectomy was the surgical treatment




Figure 2 Distribution of administration of chemotherapy in 354 patie
Ibadan in 1999–2009.excising the whole breast tissue off the chest wall inclu-
ding the axillary tail and complete axillary clearance of
lymph nodes and connective tissue up to level 3 by gen-
erous retraction of the pectoralis minor muscle. Where
involved, a portion of the underlying muscle was excised
in continuity with the breast tissue. A few patients, 7
(2.1%), were offered quadrantectomy and axillary clear-
ance. The type of surgical procedure performed was not
stated in 5 (1.2%) patients. The mode of anesthesia was
general anesthesia in 293 (82.7%) patients, local infiltra-
tion in 11 (3.0%) patients and not stated in 50 (14.3%)
patients. Most mastectomies, 239 (67.5%), were done by
consultant surgeons while the rest were performed by
resident surgeons. About a quarter of the patients re-
ceived perioperative blood transfusion, 53 (14.9%) during
surgery and 35 (10.0%) post-operatively. All the pa-
tients transfused were those with either T3 or T4 tu-
mors at presentation and the mean number of blood
units transfused was 1.9 units. The mastectomy wounds
were drained using close passive drain in 315 (88.7%) pa-
tients, close active (suction) drain in 19 (5.4%) patients
and unknown in 20 (5.9%) patients.
Post-operative care and follow up
Post-operative complications within 30 days of surgery
occurred in 51 (14.5%) patients with seroma accumula-
tion under the skin flap ranking highest in 21 (6.0%) of
the patients. Surgical wound infection occurred in 16
(4.4%) and skin flap necrosis in 6 (1.7%) patients. Other
less common post-operative events in 8 (2.3%) patients
included shoulder joint stiffness and paraesthesia of the
upper arm (Figure 5). The surgical drains were removed
between the 8th and 14th postoperative day with a mean
of 10 days. The wound drains were removed when the
output was clear or straw coloured and less than 40mls
in the preceding 24 hr period. None of the patients was
discharged home with the drain. The least and maxi-
mum duration of hospital stay from admission for mas-
















Figure 3 Neo-adjuvant chemotherapy regimens in 174 pre-mastectomy patients in Surgical Oncology Division, UCH Ibadan
in 1999–2009.
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seen at the surgical outpatients department for follow up
care for less than 2 years. At 18 months, 37.9% of the
patients were still attending the outpatients clinics, fol-
lowed thereafter by a gradual decline with most patents
lost to follow up between the 24th and 30th months post
mastectomy.
Discussion
In this review, most patients were young women, preme-
nopausal, had invasive ductal carcinoma and underwent
modified radical mastectomy as the definitive surgical
treatment. Prior to mastectomy, the tumor was down
staged in half of the patients that received neo-adjuvant
combination chemotherapy. About two-thirds and a
third of all the patients received post-operative radio-




Figure 4 Tumour responses to neo-adjuvant chemotherapy in 174 pr
in 1999–2009.operative complication was seroma collection in six per-
cent of the patients. The average hospital stay was ten
days and most patients were followed up at the surgical
outpatients department for about two years post surgery.
Surgery remains an important and essential compo-
nent of the management of breast cancer, the increa-
sing availability and utilization of adjuvant therapies
notwithstanding. In the period under review however,
only about one third of the patients with breast can-
cer received surgical treatment. This breast cancer surgery
(BCS) rate was low compared to findings from a similar
review in New Zealand where 58.6% of their patients over
a 5 year period had BCS [7]. The reasons that possibly
contributed to the low mastectomy rate in our pa-
tients include late presentation with inoperable local
or metastatic tumours necessitating only palliative or ter-









e-mastectomy patients in Surgical Oncology Division, UCH Ibadan
Table 3 Responses to neo-adjuvant chemotherapy regimens in 174 pre-mastectomy patients in Surgical Oncology
Division, UCH Ibadan in 1999-2009
Complete response Partial response Stable disease Disease progression Total (%)
AC 34 (18.8%) 29 (16.9%) 16 (9.5%) 7 (4.1%) 86 (49.3)
CAF 16 (8.8%) 11 (6.5%) 11 (6.5%) 6 (3.5%) 44 (25.3)
CMF 4 (2.3%) 5 (2.9%) - 2 (1.2%) 11 (6.4)
Others. 9 (5.0%) 11 (6.5%) 5 (2.9%) 8 (4.6%) 33 (19.0)
Total (%) 63 (34.9%) 56 (32.8%) 32 (18.9%) 23 (13.4%) 174 (100)
A, Adriamycin; C, Cyclophosphamide; F, 5-Fluorouracil; M, Methotrexate.
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loss to follow up [9].
The pattern of clinical presentation and histological
types seen in these patients were similar to earlier reports
from Nigeria and the West African sub-region [3,10-12].
Breast cancer in many developing countries is characte-
rized by late presentation, younger age at diagnosis, largeTable 4 Surgical and peri-operative care of mastectomy




Modified radical mastectomy 342 96.7
Quadrantectomy 7 2.1
Not stated 5 1.2
Mode of anaesthesia
General anaesthesia 293 82.7
Local infiltration 11 3.0




Blood transfusion (n = 88)
Intraoperative 53 14.9
Postoperative 35 10.0





Postoperative complications (n = 51)
Seroma 21 6.0
Wound infection 16 4.4
Flap necrosis 6 1.7
Others 8 2.3
Mean hospital stay (days) 12
Follow up at 18 months post mastectomy 37.9
*n = 354 unless otherwise stated.tumours and multiple nodal involvements. A recent sur-
vey in Lagos, a nearby city showed that more than four-
fifths of the patients delayed for 3 months before the
initial medical consultation [13]. The pattern of pres-
entation differs from that in the western world where
most patients are post-menopausal and present with
small sized early tumors and less aggressive disease. This
is more a reflection of the differences in the demographic
pattern of these societies than of assumed differences in
the intrinsic biology of the disease in the two populations
[10,14,15]. The predominance of invasive ductal carci-
noma is also akin to what is seen in other parts of the
world.
Although immunohistochemistry was obtained in only
half of these patients, its pattern nonetheless, tallies with
what has been previously reported from our group in
the same cohort of patients [16]. About two-thirds of
the tumors had either estrogen or progesterone receptor
positivity and one-fifth of them were Her2 neu positive.
Previous immunohistochemistry reports had suggested
that breast cancer tumors in Africans were estrogen or
progesterone receptor poor [17,18]. These findings were
unreflective of the true picture given that those studies
were done on old archival tissues in which antigen deg-
radation had occurred [19,20]. Our findings are similar
to values from other populations, including from with-
in Africa, and further support our earlier conclusion
that the pattern of hormone receptors in breast cancer
patients of African origin does not differ from others
[16,21-23].
More than half of our patients with locally advanced
cancer had positive tumour response and down staging
by the use of adjuvant chemotherapy. This supports the
role of neo adjuvant chemotherapy in our patients in
whom one in every two patients with advanced disease
can be down staged thus enhancing the prospects of
loco-regional surgical tumor extirpation. A previous re-
port from Eastern Nigeria had documented a response
rate of 81% in 32 women with locally advanced breast
cancer who received neo-adjuvant combination CAF che-
motherapy [24]. Since its inception in the early 1970s, sys-
temic chemotherapy as an adjunct to surgery has emerged










Figure 5 Complications of mastectomy in 51/354 breast cancer patients in Surgical Oncology Division, UCH Ibadan in 1999–2009.
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younger and older women with node positive breast can-
cer [26]. Anthracycline based combination chemotherapy
was the most commonly used regimen in our patients,
and this had been shown to reduce primary tumour bur-
den by at least 50% as far back as the pre-taxanes era [25].
Moreover, our patients received adjuvant radiation and
hormonal therapies as indicated as part of standard anti-
cancer treatment. Radiation therapy consisted mainly of
post mastectomy chest wall irradiation and irradiation of
localized secondary deposits in the spine, in long bones
and the brain when indicated. Documentation problems
in patients’ case files most probably account for the appa-
rently low rate of hormonal therapy in the patients.
The surgical option in almost all patients was modified
radical mastectomy (MRM). This still remains the stand-
ard surgical operation for operable breast cancer in most
parts of the world. The indications for MRM in our pa-
tients were early breast cancer (stages I and II), locally
advanced disease pre- or post-adjuvant treatment and in
select patients with metastatic disease who required
local control post systemic therapy. Only a negligible
number of our patients had breast conserving surgery
(BCS). Early presentation and the availability and exten-
sive use of adjuvant therapies have made BCS to gain
widespread usage in some parts of the world [27,28].
This is especially so in developed countries where evi-
dence now abounds that it is as effective as MRM in
early breast cancer [2,29]. Though a feasible option in
some patients, BCS is likely to remain an infrequent
surgical treatment for breast cancer in many low income
settings for a long time to come. This is because most
patients present late for treatment and more often with
poor grade tumours. Moreover, there are limitations that
are imposed by logistics such as paucity of radiotherapy
services and inefficient follow-up programmes. The inabi-
lity of patients to follow through post-surgery treatmentschedules due to low literacy levels and poverty contribute
to these challenges. Although sentinel lymph node (SLN)
biopsy has become the preferable standard to axillary dis-
section in breast cancer surgery, this was not done in any
of our patients. Going forward from this review, and with
the requisite expertise acquired, new patients that pre-
sent with no palpable lymph nodes and those with good
response to neo-adjuvant chemotherapy will be consi-
dered for this procedure. This would hopefully reduce
needless axillary clearance and its attendant risks and
complications.
Almost a quarter of the patients received blood trans-
fusion either during surgery or in the post-operative
period and transfusion occurred only in those with lo-
cally advanced tumours. Perioperative blood transfusion
in breast cancer patients had been a subject of study in
the past decade with some suggesting that blood transfu-
sion had harmful effects on outcome [30-32] and others
failing to support such notion [33,34]. Perioperative blood
usage was high in our patients. This contrasts with a 2 year
British hospital audit spanning 2004/5 in which the
transfusion rate was 3.8% for mastectomy and 20.0%
for mastectomy with immediate breast reconstruction
[35]. Though not stated in that report, the clinico-
pathological pattern and prognostic indicators in their
patients were likely to be more favourable given that
most of them were likely to present early for treatment.
The use of blood transfusion in the first and second halves
of our study period did not show a remarkable difference.
However, in our current experiences perioperative blood
usage is significantly minimal. This may partly be due to
our current standard use of neo-adjuvant treatment to
downstage the tumor in locally advanced breast cancer.
Ezeome and Adebamowo had earlier reported that
closed simple drains were cheap, simple to manage and
effectively comparable to closed suction drains for mas-
tectomy wounds [36]. These characteristics make closed
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cer surgery in low income countries and explain why
this was predominantly used in our patients. In the
study by Ezeome and Adebamowo, a higher wound in-
fection rate was associated with passive tube drains com-
pared to suction drains. In our current review, however,
the infection rate was similar to what had been reported
from other studies where closed suction drains were pre-
dominantly used [32,37]. Akin to the discussion on types
of drain is consideration of the length of drainage and
the duration of in-patient care after mastectomy. The
length of drainage seems to be directly proportional to
the duration of postoperative in-hospital care. The stan-
dard management of mastectomy drain was to remove
the drain when drainage was minimal, usually less than
40 ml over a 24-hour period or after 12–14 days which-
ever came first [37]. This protocol kept the patient in
hospital for an average of 8 to 10 days and increased the
hospital bill significantly. Some studies compared this
protocol with a policy of either no drain at all or early
drain removal and early postoperative discharge from
the hospital. The results recorded were shorter hospital
stay, no difference in surgical or psychological morbidity
and significant cost savings [37-39]. Our drain policy is
still evolving but the present practice is to admit patients
on the day before surgery, review their wound on the
5th postoperative day and discharge them as soon as the
drain can be removed thereafter.
The overall morbidity and the rates of postoperative
events in our cohort compare favorably with what have
been variously reported in literature. Seroma accumula-
tion under the skin flap was the commonest complica-
tion as has been documented in many series [8,40-42].
Factors that have been associated with seroma formation
include large dead space, irregularity of chest wall, low
concentration of endostatin (an anti-angiogenic factor),
use of electrocautery for flap dissection compared to
scalpel and modified radical mastectomy compared to
breast conserving mastectomy [8,42]. In a pooled ana-
lysis of prospectively enrolled 3107 women who had
mastectomy in 18 hospitals over a 3 year period, Et-
Tamer et al. reported an overall wound infection rate of
4.3%.8 The rate of infection in our series tallies closely
with theirs. Moreover, mastectomy was associated with
more wound issues than conservative surgery in their
series. A little above a third of the patients were atten-
ding the surgical outpatients department 24 months
after mastectomy. The reasons for loss of many to
long time follow up are not known, thus the survival
pattern in this cohort might never be determined.
However, a previous Nigerian study reported a me-
dian survival of 31 months with survival advantage for
post-menopausal women and in those with early stage
disease [43].Conclusions
Modified radical mastectomy remains the standard the-
rapeutic surgical operation for breast cancer in Nigeria.
Though many patients present late for treatment, tumor
down-staging with neo-adjuvant chemotherapy enhances
surgical loco-regional tumor control in some of them.
The overall morbidity and the rates of postoperative
events are minimal and comparable to what obtain in
other parts of the world. However, long-term follow-up
is still a challenge as many patients are lost to follow up
after two years of mastectomy. This review has limita-
tions due to its retrospective nature. The case notes of
some of the patients that had mastectomy were not
available for review as at the time of the study. Moreover
some data were missing from some case notes such that
the denominator was not uniform for all the variables
that were analyzed. Furthermore, the pattern of survival
of the patients post-mastectomy cannot be determined
because of inadequate follow up records and information.
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